Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...
The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...
China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...
On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...
Shanghai Rongsheng Biotech Co., Ltd is preparing to conduct an initial public offering (IPO) of...
China-based Livzon Pharmaceutical Group (HKG: 1513) has announced the national promotion of its recombinant novel...
China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...
China’s Wuhan Institute of Biological Products, a research affiliate of Sinopharm’s China National Biotech Group...
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...
The Center for Drug Evaluation (CDE) has released the “Tumor Therapeutic Vaccines Clinical Trial Technical...
Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has...
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...
China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...
Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...